Several other equities research analysts also recently weighed in on BHC. Mizuho increased their price target on Bausch Health Companies from $39.00 to $41.00 and gave the stock a buy rating in a research report on Monday, March 18th. Wells Fargo & Co increased their price target on Bausch Health Companies from $9.00 to $25.19 and gave the stock an underperform rating in a research report on Tuesday, February 19th. Cantor Fitzgerald reaffirmed a buy rating and set a $32.00 price target on shares of Bausch Health Companies in a research report on Thursday, April 25th. HC Wainwright reaffirmed a buy rating on shares of Bausch Health Companies in a research report on Thursday, February 28th. Finally, Bank of America reaffirmed an underperform rating and set a $18.00 price target on shares of Bausch Health Companies in a research report on Wednesday, March 20th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the company. Bausch Health Companies presently has a consensus rating of Hold and an average target price of $27.99.
NYSE BHC opened at $24.44 on Monday. The company has a debt-to-equity ratio of 8.61, a quick ratio of 0.83 and a current ratio of 1.08. Bausch Health Companies has a 1 year low of $17.20 and a 1 year high of $28.45. The firm has a market capitalization of $8.82 billion, a P/E ratio of 6.08, a PEG ratio of 0.58 and a beta of 0.55.
Bausch Health Companies (NYSE:BHC) last released its earnings results on Monday, May 6th. The company reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $0.14. Bausch Health Companies had a positive return on equity of 47.01% and a negative net margin of 19.27%. The firm had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $2.03 billion. During the same period in the prior year, the firm earned $0.89 EPS. The firm’s revenue was up 1.1% on a year-over-year basis. On average, analysts expect that Bausch Health Companies will post 4.06 earnings per share for the current fiscal year.
In related news, CEO Joseph C. Papa purchased 30,000 shares of the business’s stock in a transaction on Thursday, February 28th. The shares were bought at an average cost of $23.67 per share, with a total value of $710,100.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 11.87% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in BHC. FIL Ltd boosted its stake in shares of Bausch Health Companies by 69.6% during the 1st quarter. FIL Ltd now owns 10,545,300 shares of the company’s stock worth $260,170,000 after acquiring an additional 4,327,851 shares in the last quarter. Norges Bank purchased a new stake in shares of Bausch Health Companies during the 4th quarter worth about $59,054,000. Orbimed Advisors LLC boosted its stake in shares of Bausch Health Companies by 89.1% during the 4th quarter. Orbimed Advisors LLC now owns 3,600,300 shares of the company’s stock worth $66,498,000 after acquiring an additional 1,696,400 shares in the last quarter. Ardevora Asset Management LLP boosted its stake in shares of Bausch Health Companies by 1,894.8% during the 4th quarter. Ardevora Asset Management LLP now owns 1,638,120 shares of the company’s stock worth $30,256,000 after acquiring an additional 1,556,002 shares in the last quarter. Finally, Bank of Montreal Can boosted its stake in shares of Bausch Health Companies by 28.2% during the 1st quarter. Bank of Montreal Can now owns 3,702,077 shares of the company’s stock worth $91,441,000 after acquiring an additional 815,311 shares in the last quarter. 54.70% of the stock is currently owned by institutional investors.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Further Reading: Buyback
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.